William G. Bornmann

The University of Texas MD Anderson Cancer Center — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

71h-index18.2kcitations284works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer therapeutics and mechanisms(43), Chronic Myeloid Leukemia Treatments(40), Bioactive Compounds and Antitumor Agents(36), ATP Synthase and ATPases Research(29), Ubiquitin and proteasome pathways(28)

Publications284 total

Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
Leukemia·2024Open Access
Data from Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy
2023Open Access
Data from Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy
2023Open Access
Data from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
2023Open Access
Data from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
2023Open Access
Supplemental Figure Legends from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
2023Open Access
Supplementary Materials and Methods from Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy
2023Open Access
Supplementary Figures and Table from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
2023Open Access
Data from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
2023Open Access
Supplementary Figures and Table from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
2023Open Access
Supplemental Figures 1-6 and Supplemental Tables 1-3 from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
2023Open Access
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
2023Open Access
Data from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
2023Open Access
Data from Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers
2023Open Access
Supplementary Materials and Methods from Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy
2023Open Access
Data from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
2023Open Access
Supplemental Figures 1-6 and Supplemental Tables 1-3 from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
2023Open Access
Supplementary Tables 1 and 2 and Supplementary Figures 1 through 7 from Evaluation of Apoptosis Induction by Concomitant Inhibition of MEK, mTOR, and Bcl-2 in Human Acute Myelogenous Leukemia Cells
2023Open Access
Supplemental Figure Legends from NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer
2023Open Access
Supplementary Data from c-Jun-NH<sub>2</sub>-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer
2023Open Access
page 1 of 15Next →

Frequent Co-authors

Darren R. Veach(10), David A. Boothman(6), Bayard Clarkson(5), Jinming Gao(5), Juri G. Gelovani(5), John Kuriyan(4), Moshe Talpaz(4), Nicholas J. Donato(4), Erik A. Bey(4), Ronald D. Finn(4), Mikhail Doubrovin(4), Julius Balatoni(4), Ronald G. Blasberg(4), Daniel Kalman(4), Zhenghong Peng(4), Thomas H. Schindler(3), Bhushan Nagar(3), Bayard D. Clarkson(3), Jacqueline Bromberg(3), Steven M. Larson(3)